Special Issue

Mechanisms and Novel Therapeutic Approaches for Muscle Disease

Message from the Guest Editors

Muscular dystrophy is a group of inherited rare diseases that causes progressive weakness and the degeneration of skeletal and cardiac muscles, with or without damaging the nerve supplied to the muscles. The diseases often affect a particular group of muscles before spreading more widely to other muscle groups, increasing the level of disability and possible deformity or even becoming life-threatening when cardiac or/and respiratory muscles are severely impaired. This Special Issue on "Mechanisms and Novel Therapeutic Approaches for Muscle Disease" therefore welcomes basic to translational research studies that aim to provide up-to-date insights into pathophysiological mechanisms, innovative methodologies, cellular and animal models, and novel therapeutic strategies that have a great potential for the development of a cure or modifying treatments for muscular dystrophies.

Guest Editors

Dr. Ngoc B. Lu-Nguyen

Royal Holloway, University of London, Egham Hill, TW20 0EX Egham, Surrey, UK

Prof. Dr. Linda Popplewell

1. National Horizons Centre, Teesside University, Darlington DL1 1HG, UK
2. Department of Biological Sciences, School of Life Sciences and the Environment, Royal Holloway University of London, Egham TW20 0EX, UK

Deadline for manuscript submissions

closed (31 December 2023)

Biomedicines

an Open Access Journal by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed

mdpi.com/si/131495

Biomedicines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
biomedicines@mdpi.com

mdpi.com/journal/biomedicines

Biomedicines

an Open Access Journal by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed

mdpi.com/journal/biomedicines

MDPI

About the Journal

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to Biomedicines, be it original research, review articles, or developing Special Issues of current key topics.

Editor-in-Chief

Prof. Dr. Felipe Fregni
1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17 days after submission; acceptance to publication is undertaken in 2.9 days (median values for papers published in this journal in the first half of 2025).